Limitations on today's technology
QuiaPEG's advantages

QuiaPEG's Proprietary Pegylation Platform 

To address the shortcomings of current methods, QuiaPEG has developed a practical method for synthesis and purification of activated PEG reagents, resulting in a highly homogeneous PEG. This proprietary PEG material, together with novel PEGylation methods and purification protocols, enables simple and efficient PEGylation and subsequent purification of the PEGylated product. 

The innovation is based on the introduction of a specific activating/functionalizing group to the PEG molecule allowing simultaneous isolation of mono-functionalized fraction of PEG. Another characteristic of QuiaPEGs methodology is a novel bridge which links the PEG chain to its functional group, and finally, to the protein or peptide.

Additionally, QuiaPEGs method allows for easy detection and characterization of any remaining impurities present in a particular batch of PEG as well as defining the grade of its purity. Using this proprietary material in PEGylation enables a faster and cheaper process, which compared to current PEGylation technologies results in higher yield, fewer impurities and a more homogenous end product. The link between the PEG polymer and the protein/peptide is both chemically and enzymatically stable.

Therapeutic advantages

  • Half-life extension
  • Less frequent dosing -> increased patient convenience
  • Improved solubility/stability

Drug development and regulatory advantages

  • Versatile platform offers designed solutions
  • Higher success rate using clinically validated parent drug
  • Superior purity/quality of reagents -> higher yields -> reduced cost-of-goods

Intellectual Property

  • Suitable for new composition of matter patents/life-cycle management
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message